Study short name

MIS BAIR (Melbourne Infant Study: BCG for Allergy & Infection Reduction)

Study full name

A randomised, controlled trial to determine if BCG immunisation at birth prevents the development of allergy & infection in infants

Principle Investigator

Nigel Curtis

Administering Institute

Murdoch Children’s Research Institute

Major funding sources

National Health and Medical Research Council (NHMRC), Royal Children’s Hospital Foundation, University of Melbourne and Murdoch Children’s Research Institute

Study focus


Study design


Main study aim

To assess whether the BCG vaccine will prevent food allergy, eczema and lower respiratory tract infections in the first 5 years of life.

Additional study information

Study participants randomised to group 1 received a single 0.05 mL intradermal injection of BCG Vaccine SSI or BCG 10 Vaccine over the distal insertion of the deltoid muscle onto the humerus approximately one third down the upper left arm.

Study population

1272 healthy newborns randomised in the first 10 days of life.

Study status

Recruitment completed September 2016. Data collection ongoing, through February 2022.